Biohaven's Troriluzole Could Drive Potential Upside if the Company Overcomes Regulatory Hurdles, RBC Says

MT Newswires Live06-25 23:26

Biohaven's (BHVN) troriluzole to treat neurodegenerative diseases could see up to a 100% upside if the company overcomes regulatory hurdles amid the US Food and Drug Administration's more sponsor-friendly stance, RBC Capital Markets said in a Thursday note.

Considering shares as undervalued on epilepsy and degrader programs, the analysts said the drug candidate could make for an even more interesting setup for the stock.

According to the note, factors that could support FDA leniency for troriluzole include its largely safe and well-tolerated data and design to target a rare disease with no approved treatments.

RBC reiterated its outperform rating on the stock and adjusted its price target to $22 from $23.

Price: 15.51, Change: +0.55, Percent Change: +3.68

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646048238?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 23:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646048238","market":"nz","top_or_hot":-1,"title":"Biohaven's Troriluzole Could Drive Potential Upside if the Company Overcomes Regulatory Hurdles, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Biohaven's (BHVN) troriluzole to treat neurodegenerative diseases could see up to a 100% upside if the company overcomes regulatory hurdles amid the US Food and Drug Administration's more sponsor-friendly stance, RBC Capital Markets said in a Thursday note.</p><p>Considering shares as undervalued on epilepsy and degrader programs, the analysts said the drug candidate could make for an even more interesting setup for the stock.</p><p>According to the note, factors that could support FDA leniency for troriluzole include its largely safe and well-tolerated data and design to target a rare disease with no approved treatments.</p><p>RBC reiterated its outperform rating on the stock and adjusted its price target to $22 from $23.</p><p>Price: 15.51, Change: +0.55, Percent Change: +3.68</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven's Troriluzole Could Drive Potential Upside if the Company Overcomes Regulatory Hurdles, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven's Troriluzole Could Drive Potential Upside if the Company Overcomes Regulatory Hurdles, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-25 23:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Biohaven's (BHVN) troriluzole to treat neurodegenerative diseases could see up to a 100% upside if the company overcomes regulatory hurdles amid the US Food and Drug Administration's more sponsor-friendly stance, RBC Capital Markets said in a Thursday note.</p><p>Considering shares as undervalued on epilepsy and degrader programs, the analysts said the drug candidate could make for an even more interesting setup for the stock.</p><p>According to the note, factors that could support FDA leniency for troriluzole include its largely safe and well-tolerated data and design to target a rare disease with no approved treatments.</p><p>RBC reiterated its outperform rating on the stock and adjusted its price target to $22 from $23.</p><p>Price: 15.51, Change: +0.55, Percent Change: +3.68</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756325.SGD","symbol_name":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2646048238","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646048238","pubTimestamp":1782401212,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biohaven's  troriluzole to treat neurodegenerative diseases could see up to a 100% upside if the company overcomes regulatory hurdles amid the US Food and Drug Administration's more sponsor-friendly stance, RBC Capital Markets said in a Thursday note.Considering shares as undervalued on epilepsy and degrader programs, the analysts said the drug candidate could make for an even more interesting setup for the stock.According to the note, factors that could support FDA leniency for troriluzole include its largely safe and well-tolerated data and design to target a rare disease with no approved treatments.RBC reiterated its outperform rating on the stock and adjusted its price target to $22 from $23.Price: 15.51, Change: +0.55, Percent Change: +3.68","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4139":"生物科技","BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"translate_title":"加拿大皇家银行表示，如果Biohaven克服监管障碍，其曲鲁唑可能会带来潜在的上涨空间","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":1},"content_text":"Biohaven's (BHVN) troriluzole to treat neurodegenerative diseases could see up to a 100% upside if the company overcomes regulatory hurdles amid the US Food and Drug Administration's more sponsor-friendly stance, RBC Capital Markets said in a Thursday note.Considering shares as undervalued on epilepsy and degrader programs, the analysts said the drug candidate could make for an even more interesting setup for the stock.According to the note, factors that could support FDA leniency for troriluzole include its largely safe and well-tolerated data and design to target a rare disease with no approved treatments.RBC reiterated its outperform rating on the stock and adjusted its price target to $22 from $23.Price: 15.51, Change: +0.55, Percent Change: +3.68","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646048238","isCrawlerRequest":true}